Reliance Life Sciences

India could step up to the plate with a vaccine to prevent mpox, classified as a public health emergency of international concern (PHEIC) once again post 2022 by the World Health Organization (WHO) af

Aurobindo Pharma is conducting Phase III trials for a biosimilar to multi-billion immunology product Xolair (omalizumab), originally developed and sold by Roche unit Genentech and Novartis , CEO

Glenmark Pharmaceuticals Limited has slashed prices of its trastuzumab biosimilar by over 70% in India, seeking to expand access to the breast cancer therapy in a predominantly self-pay market where

Aurobindo Pharma Limited is conducting Phase III trials for a biosimilar to multi-billion immunology product Xolair (omalizumab), originally developed and sold by Roche Holding AG unit Genentech,